ProCE Banner Activity

Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC

Slideset

Download these slides from an expert-led webinar on novel agents targeting HER3 in NSCLC

Released: April 03, 2023

Share

Faculty

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Helena Yu, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Blueprint, Daiichi Sankyo, Janssen, Taiho.